The mission of the DF/HCC Monoclonal Antibody Core (MAC) is to produce novel monoclonal antibodies that are directed against antigens of interest to Dana-Farber, the Harvard Cancer Center, and affiliated investigators. These monoclonal antibodies may be useful for basic research, drug discovery and clinical applications including diagnosis, surrogate markers for disease status, response to therapy or drug toxicity.
Given the diverse research needs of investigators at DFCI and the Harvard Community, the MAC should strive to support a wide range of antibody requests. A key component of the DF/HCC MAC is the ability to explore and develop new technologies that facilitate generation of monoclonal antibodies. The DF/HCC MAC should be capable of supporting all basic functions of generating, screening, storing and producing monoclonal antibodies.
Leadership and Staff
Core Director: James Decaprio, MD
Facility Director: Edward Greenfield, PhD
Craig Bencsics, PhD
Mohan Brahmandam, PhD
Yuhua Nong, MD
PUBLICATION ACKNOWLEDGEMENT: If research supported by this core facility results in publication, please acknowledge this support by including the following in your publication(s):
We thank Dana-Farber/Harvard Cancer Center in Boston, MA, for the use of the Monoclonal Antibody Core, which provided __________ service. Dana-Farber/Harvard Cancer Center is supported in part by an NCI Cancer Center Support Grant # NIH 5 P30 CA06516.